Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

NCT04969731 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

408

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Immuncell-LC
DRUG: Gemcitabine

Sponsor

GC Cell Corporation